Type 2 Diabetes Drug XOMA 052 Takes Anti-Inflammatory Approach


XOMA 052 type 2 diabetes treatment drug has undergone phase 2b of its clinical trial. The 325-patient trial will be conducted at up to 70 U.S. Sites. Multiple dose level of XOMA 052 will be analyzed in the placebo-controlled trial. The company that specializes in antibody therapy is hoping this phase will guide them into phase 3.

XOMA is aiming for a first quarter 2011 study release date. Type 2 diabetes patients will be administered a subcutaneous injection of stable metformin therapy or a placebo-controlled substance. Metformin is a widely used anti-diabetes treatment drug that is sometimes paired with insulin treatment.

"XOMA 052, an antibody to interleukin-1 beta, is a potential paradigm-shifting treatment for Type 2 diabetes and cardiovascular disease and other inflammatory diseases," stated Steven B. Engle, XOMA Chairman and Chief Executive Officer. "The Phase 2b trial initiation is another major milestone in the XOMA 052 program."


The company has decided to limit its disclosure regarding the phase 2 trial because of competitor infiltration of the study. The new drug “is a potent monoclonal antibody with the potential to improve the treatment of patients with a wide variety of inflammatory diseases.” XOMA 052 binds to interleukin-1 beta (IL-1 beta), which is a pro-inflammatory cytokine.

Cytokines are small proteins that trigger inflammation and respond to infections. The reactions between these factors can lead to the development of type 2 diabetes, cardiovascular disease, rheumatoid arthritis and gout.

XOMA 052 inhibits the activation of the IL-1 receptor, which stops the cytokines from signaling triggers that produce inflammation. The biotechnology company owns worldwide rights to antibody therapy and plans on developing and commercializing XOMA 052 after the successful clinical trials are completed.

Reference: XOMA